Minireviews
Copyright ©The Author(s) 2021.
World J Clin Cases. Jan 26, 2021; 9(3): 521-527
Published online Jan 26, 2021. doi: 10.12998/wjcc.v9.i3.521
Table 1 Basic characteristics of patients in clinical studies of “argon plasma coagulation combined with endoscopic variceal ligation” vs “endoscopic variceal ligation alone” in treatment of esophageal varices
Ref.
Country
Sample size (EVL+APC/EVL)
Age (EVL+APC/EVL) (mean ± SD)
Gender (male/female)
Liver function classification (EVL+APC/EVL)
Pathogenic factors (EVL+APC/EVL)
Varicose vein types (EVL+APC/EVL)
Follow-up (EVL+APC/EVL) (mean ± SD)
Nakamura et al[11]. 2001Japan30/3063.7 ± 5.8/60.8 ± 7.1EVL+APC: 22/8; EVL: 21/9A: 9/7; B: 17/18; C: 4/5Virus: 25/26; Alcohol: 4/4; Others: 1/0F2: 19/17; F3: 11/1318.5 ± 6.8/15.8 ± 7.7
Cipolletta et al[20]. 2002Italy16/1462.8 ± 5.5/60.8 ± 6.2EVL+APC: 11/5; EVL: 10/4Not mentionedNot mentionedF2: 10/9; F3: 6/516.2 ± 5.8/16.5 ± 5.1
Harras et al[20]. 2010Egypt50/5050.64 ± 10.43/48.96 ± 10.27Not mentionedA: 10/14; B: 34/32; C: 6/4Virus: 50/50; Alcohol: 0/0; Others: 0/0F2: 3/0; F3: 47/5016.3/17.4
Hamza I et al[21]. 2012Egypt30/3050.23 ± 2.095/50 ± 2.104EVL+APC: 16/14; EVL: 18/12The two groups have the highest proportion of B grade, and there is no difference between the groupsNot mentionedPost operative 3 mo: F0: 18/15; F1: 12/15; F2: 0/0Follow-up 3 mo and 6 mo
Kamal et al[13]. 2017Egypt20/2048.4/47.8Not mentionedA:12/12; B: 6/6; C: 2/2Virus: 20/20; Alcohol: 0/0; Others: 0/0Not mentionedNot mentioned
Table 2 Clinical results of “argon plasma coagulation combined with endoscopic variceal ligation” vs “endoscopic variceal ligation alone” in treatment of esophageal varices

Nakamura et al[11], 2001
Cipolletta et al[19], 2002
Harras et al[20], 2010
Hamza I et al[21], 2012
Kamal et al[13], 2017
GroupEVL+APCEVLEVL+APCEVLEVL+APCEVLEVL+APCEVLEVL+APCEVL
Sample size30301614505030302020
Varicose veinsNo recurrence 74.2%No recurrence 49.6%Recurrence 0%Recurrence 42.8%Recurrence 4%Recurrence 28%Post operative 6 mo; F0: 16; F1: 14; F2: 0Post operative 6 mo; F0: 10; F1: 19; F2: 1Recurrence 21.1%Recurrence 68.4%
Recurrent bleeding3.3%6.7%0%7.2%2%8%0%0%0%10.5%
Fever63.3%33.3%81.3%0%34%8%6.7%6.7%60%15%
Difficulty swallowing30%26.7%50%0%36%12%3.3%3.3%35%30%
Esophageal stenosis3.3%0%0%0%0%0%0%0%0%0%
Mortality0%0%0%0%8%12%0%0%5%5%
Eradication course2.9 ± 0.62.5 ± 0.6Not mentionedNot mentioned4.6 ± 0.73.7 ± 0.54.434.23Not mentionedNot mentioned